Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Vedere Bio, a venture based optogenetics company in Cambridge, Massachusetts. Vedere had developed… Read More »Novartis AG has acquired optogenetics company Vedere Bio for a value up to $280M.
Clinical researchers at the NHS Foundation Trust, Sheffield, UK have found that real-world evidence on the effectiveness and safety of a fluocinolone acetonide (FAc) implant… Read More »Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.
Researchers at the Department of Ophthalmology, Universidade Federal de Sao Paulo, Brazil, have reported on a new clinical study detecting 38 new gene variants among… Read More »Research on Leber congenital amaurosis (LCA) on a Brazilian cohort of 152 patients has identified almost 40 new genetic variants and 4 new complex alleles
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 17th, 2020 edition of EURETINA’s web-based digital magazine,… Read More »November 17th, 2020: “EURETINA-Brief”© Issue No. 224
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***